In a patient with inferior‑wall myocardial ischemia, how should isosorbide dinitrate (ISDN) be administered, including indications, dosing, and monitoring?

ISDN Administration in Inferior Wall Ischemia

Isosorbide dinitrate (ISDN) should be used cautiously in inferior wall myocardial ischemia, primarily for symptom relief of ongoing chest pain or hypertension, but must be avoided if right ventricular (RV) infarction is suspected—a common complication of inferior MI that can lead to catastrophic hypotension with nitrate administration. 1

Critical Contraindication: Right Ventricular Involvement

The most important consideration with inferior wall ischemia is the high likelihood of RV involvement. Nitrates are absolutely contraindicated in suspected RV infarction because they reduce preload, which is essential for maintaining cardiac output in RV dysfunction. 1 This can precipitate severe hypotension and cardiogenic shock.

Before Administering ISDN:

• Check blood pressure: Avoid if systolic BP <90 mm Hg or >30 mm Hg below baseline 1
• Assess for RV infarction signs: ST elevation in right-sided leads (V4R), hypotension with clear lungs, elevated JVP
• Rule out recent phosphodiesterase-5 inhibitor use (within 24-48 hours) 1

Indications for ISDN Use

ISDN is indicated for:

• Ongoing chest pain despite initial therapy 1
• Hypertension complicating acute coronary syndrome 1
• Heart failure symptoms (if RV infarction excluded) 1

Dosing Regimens

Sublingual Administration (Acute Symptom Relief)

• Initial dose: 2.5-5 mg sublingually 2
• Can repeat every 5 minutes up to 3 doses as blood pressure allows 1
• Onset of action is rapid, with therapeutic effects evident within 3 minutes 3

Intravenous Administration (Sustained Effect)

• Start at 10 mcg/min IV 1
• Titrate upward to achieve desired blood pressure effect or symptom relief 1
• IV ISDN demonstrates faster onset (3 minutes) compared to mononitrate formulations (15 minutes) for acute ischemic episodes 3

Important Caveats and Monitoring

Tolerance Development

Research shows early tolerance can develop even within the first dosing cycle—antiischemic effects diminish from 59% ST-segment reduction at 2 hours to 42% at 4.5 hours after the first dose. 4 This is clinically relevant but should not deter acute use for symptom management.

Lack of Mortality Benefit

Large trials (GISSI-3, ISIS-4) demonstrated that routine nitrate administration does not reduce mortality in acute MI. 5 One study specifically examining sublingual ISDN (10 mg every 2 hours for 72 hours) in inferior MI showed no reduction in infarct size measured by CK levels or QRS scoring. 6 Therefore, ISDN should be reserved for symptomatic management, not routine prophylaxis.

Monitoring Parameters

• Blood pressure: Check before each dose and continuously with IV administration
• Heart rate: Watch for reflex tachycardia or bradycardia
• Symptoms: Assess chest pain relief
• Signs of hypotension: Dizziness, altered mental status, decreased urine output
• ECG changes: Monitor for worsening ischemia if hypotension develops

Clinical Algorithm

1. Confirm inferior wall ischemia (ST elevation in leads II, III, aVF)
2. Obtain right-sided ECG to rule out RV involvement
3. Check blood pressure and recent medication history
4. If BP adequate and no RV involvement:
   • Give 2.5-5 mg sublingual ISDN for ongoing pain 2
   • Repeat every 5 minutes × 3 doses maximum 1
   • If persistent symptoms, consider IV infusion starting at 10 mcg/min 1
5. If hypotension or RV infarction: Avoid nitrates entirely—use IV fluids for preload augmentation instead

Key Pitfall to Avoid

The most dangerous error is administering nitrates to a patient with RV infarction complicating inferior MI. Always obtain right-sided ECG leads and assess hemodynamics before giving any nitrate in inferior wall ischemia. The combination of reduced preload from nitrates and impaired RV function can cause irreversible hemodynamic collapse.